Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 253-264

  Curet, Olivier ^a   Damoiseau, Gabrielle ^a   Aubin, Nadine ^a   Sontag, Nicole ^a   Rovei, Vincenzo ^a   Jarreau, Francois Xavier ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYLPHENOXATHIIN 10,10 DIOXIDE; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 (4 CYANOANILINO) 6,7 DIHYDRO 7 HYDROXY 5H CYCLOPENTA[D]PYRIMIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BEFLOXATONE; BENZYLAMINE OXIDASE; BROFAROMINE; CIMOXATONE; CLOMIPRAMINE; DESIPRAMINE; DIMINAZENE ACETURATE; DOPAMINE; HARMALINE; MOCLOBEMIDE; MONOAMINE; MONOAMINE OXIDASE A INHIBITOR; NORADRENALIN; OXAZOLIDINONE DERIVATIVE; PRAZOSIN; SEROTONIN; TOLOXATONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME LOCALIZATION; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PTOSIS; RAT; TREMOR;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; DUODENUM; HUMANS; LIVER; MALE; METHOXYHYDROXYPHENYLGLYCOL; MONOAMINE OXIDASE INHIBITORS; OXAZOLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030431043     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. 3H]-quinuclidinyl benzilate. Mol. Pharmacol. 22: 304-309, 1982.
2. BACH, A. W. J., LAN, N. C., JOHNSON, D. L., ABELL, C. W., BEMBENEK, M. E., KWAN, S. W., SEEBURG, P. H. AND SHIH, J. C.: cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. U.S.A. 85: 4934-4938, 1988.
3. 3 recognition sites. J. Pharm. Pharmacol. 40: 548-551, 1988.
4. BIECK, P. R. AND ANTONIN, K.-H.: Tyramine potentiation during treatment with MAOIs. In Clinical Advances in Monoamine Oxidase Inhibitor Therapies, ed. by S. H. Kennedy, pp. 83-110, American Psychiatry Press, Washington, D.C., 1994.
5. 3H]-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 35: 1885-1893, 1984.
6. BLACKWELL, B.: Adverse effects of antidepressant drugs. Part 1. Monoamine oxidase inhibitors and tricyclics. Drugs 21: 201-219, 1981.
7. BUFFONI, F.: Biochemical pharmacology of amine oxidases. Trends Pharmacol. Sci. 4: 313-315, 1983.
8. BURKARD, W. P. AND KETTLER, R.: Harmaline and its sulfur analogue: Increase of cerebellar cyclic GMP and inhibition of monoamine oxidase. Biochem. Pharmacol. 26: 1303-1306, 1977.
9. CALLINGHAM, B. A. AND BARRAND, M. A.: Some properties of semicarbazide-sensitive amine oxidases. J. Neural Transm. 23: (Suppl.) 37-54, 1987.
10. CAILLE, D., BERGIS, O.-E., FANKHAUSER, C., GARDES, A., ADAM, R., CHARIERAS, T., GROSSET, A., ROVEI, V. AND JARREAU, F.-X.: Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J. Pharmacol. Exp. Ther. 277: 265-277, 1996.
11. 3H]-mepyramine. Eur. J. Pharmacol. 48: 463-464, 1978.
12. CHUANG, H. Y. K., PATEK, D. R AND HELLERMAN, L.: Mitochondrial monoamine oxidase. Inactivation by pargyline. Adduct formation. J. Biol. Chem. 249: 2381-2384, 1974.
13. CURET, O., DAMOISAU, G. AND AUBIN, N.: Biochemical profile of befloxatone, a new reversible MAO-A inhibitor. Clin. Neuropharmacol. 15: 423b, 1992.
14. DA PRADA, M., KETTLER, R., KELLER, H. H., BURKARD, W. P., MUGGLI-MANIGLIO, D. AND HAEFELY, W. E.: Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248: 400-414, 1989.
15. EISENHOFER, G., GOLDSTEIN, D. S., STULL, R., KEISER, H. R., SUNDERLAND, T., MURPHY, D. L. AND KOPIN, I. J.: Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxydase. Clin. Chem. 32: 2030-2033, 1986.
16. EISENHOFER, G., GOLDSTEIN, D. S., ROPCHAK, T. G., NGUYEN, H. Q., KEISER, H. R. AND KOPIN, I. J.: Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J. Auton. Nerv. Syst. 24: 1-14, 1988.
17. EKSTEDT, B.: Substrate specificity of the different forms of monoamine oxidase in rat liver mitochondria. Biochem. Pharmacol. 25: 1133-1138, 1976.
18. ELSWORTH, J. D., GLOVER, V., REYNOLDS, G. P., SANDLER, M., LEES, A. J., PHUAPRADIT, P., SHAW, K. M., STERN, G. M. AND KUMAR, P.: Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the "cheese effect." Psychopharmacology 57: 33-38, 1978.
19. EULER, U. S. AND LISHAJKO, F.: Release of noradrenaline from adrenergic transmitter granules by tyramine. Experientia 16: 376-377, 1960.
20. 3H]-desmethoxyverapamil labelling of putative calcium channels in brain: Autoradiographic distribution and allosteric coupling to 1,4-dihydropyridine and diltiazem binding sites. Naunyn-Schmiedeberg's Arch. Pharmacol. 327, 183-187, 1984.
21. FOWLER C. J. AND CALLINGHAM, B. A.: The inhibition of rat heart type A monoamine oxidase by clorgyline as a method for the estimation of enzyme active centers. Mol. Pharmacol. 16: 546-555, 1979.
22. FOWLER, C. J AND STROLIN-BENEDETTI, M.: The metabolism of dopamine by both forms of monoamines oxidase in the rat brain and its inhibition by cimoxatone. J. Neurochem. 40: 1534-1541, 1983a.
23. FOWLER, C. J. AND STROLIN BENEDETTI, M.: Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. J. Neurochem. 40: 510-513, 1983b.
24. GOLDSTEIN, D. S., EISENHOFER, G., STULL, R., FOLIO, C. J., KEISER, H. R. AND KOPIN, I. J.: Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J. Clin. Invest. 81: 213-220, 1988.
25. GREEN, A. R. AND YOUDIM, M. B. H.: Effects of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br. J. Pharmacol. 55: 415-422, 1975.
26. GREENAWALT, J. W. AND SCHNAITMAN, C.: An appraisal of the use of monoamine oxidase as an enzyme marker for the outer membrane of rat liver mitochondria. J. Cell Biol. 46: 173-179, 1970.
27. HAEFELY, W., HURLIMANN, A. AND THOENEN, H.: The responses to tyramine of the normal and denervated nictitating membrane of the cat: Analysis of the mechanisms and sites of action. Br. J. Pharmacol. 21: 27-38, 1963.
28. HASAN, F., MCCRODDEN, J. M., KENNEDY, N. P. AND TIPTON, K. F.: The involvement of intestinal monoamine in the transport and metabolism of tyramine. J. Neural Transm. 26: (Suppl.) 1-9, 1988.
29. HORNUNG, R., PRESEK, P. AND GLOSSMANN, H.: Alpha adrenoceptors in rat brain - Direct identification with prazosin. Naunyn-Schmiedeberg's Arch. Pharmacol. 308: 223-230, 1979.
30. HSU, Y. P. P., WEYLER, W., CHEN, S., SIMS, K. B., RINEHART, W. B., UTTERBACK, M. C., POWELL, J. F. AND BREAKEFIELD, X. O.: Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J. Neurochem. 51: 1321-1324, 1988.
31. JONES-HUMBLE, S. A., NORTON, R. M., WHITE, H. L. AND COOPER, B. R.: BW 1370U87, a new monoamine oxidase A inhibitor: Effects on biogenic amine neurotransmitter and metabolite levels in rat brain. Drug Dev. Res. 25: 201-207, 1992.
32. JOHNSTON, J. P.: Some observations upon a new inhibitor of monoamine oxydase in brain tissue. Biochem. Pharmacol. 17: 1286-1297, 1968.
33. KAN, J.-P., STEINBERG, R., LECLERCQ, J., WORMS, P. AND BIZIERE, K.: Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: Evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro. J. Neurochem. 50: 1137-1144, 1988.
34. KAN, J.-P., STEINBERG, R., MOUGET-GONIOT, C., WORMS, P. AND BIZIERE, K.: SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. J. Pharmacol. Exp. Ther. 240: 251-258, 1987.
35. KAN, J.-P. AND STROLIN-BENEDETTI, M.: Characteristics of the inhibition of rat brain monoamine oxidase in vitro by MD780515. J. Neurochem. 36: 1561-1571, 1981.
36. 2-adrenoceptor. Eur. J. Pharmacol. 117: 43-50, 1985.
37. KNOLL, J. AND MAGYAR, K.: Some puzzling pharmacological effects of monoamines oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5: 393-408, 1972.
38. KOE, B. K.: Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J. Pharmacol. Exp. Ther. 199: 649-661, 1976.
39. KONRADI, C., KORNHUBER, J., FROELICH, L., FRITZE, J., HEINSEN, H., BECKMANN, H., SCHULZ, E. AND RIEDERER, P : Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 33: 383-400, 1989.
40. KONRADI, C., SVOMA, E., JELLINGER, K., RIEDERER, P., DENNEY, R. AND THIBAULT, J.: Topographic immunocytochemical mapping of monoamine oxidase A, monoamine oxidase B and tyrosine hydroxylase in human post mortem brain stem. Neuroscience 26: 791-802, 1988.
41. KOULU, M., SCHEININ, M., KAARTTINEN, A., KALLIO, J., PYYKKO, K., VUORINEN, J. AND ZIMMER, R. H.: Inhibition of monoamine oxidase by moclobemide: Effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br. J. Clin. Pharmacol. 27: 243-265, 1989.
42. KUMAGAE, Y., MATSUI, Y. AND IWATA, N.: Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn. J. Pharmacol. 55: 121-128, 1991.
43. LAN, N. C., CHEN, C. AND SHIH, J. C.: Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells. J. Neurochem. 52: 1652-1654, 1989.
44. LEVITT, P., PINTAR, J. E. AND BREAKEFIELD, X. O.: Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. U.S.A 79: 6385-6389, 1982.
45. 2 receptor binding sites. Mol. Pharmacol. 21: 301-314, 1982.
46. LI, P. P , WARSH, J. J. AND GODSE, D. D.: Further characterization of brain 3,4-dihydroxyphenylethyleneglycol (DHPG) formation: Dependence on noradrenergic activity and site of formation. Naunyn-Schmiedeberg's Arch. Pharmacol. 332: 26-33, 1986.
47. 3H]-raclopride. Proc. Natl. Acad. Sci. U.S.A. 86: 6412-6416, 1989.
48. LIPPER, S., MURPHY, D. L., SLATER, S. AND BUCHSBAUM, M. S.: Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation. Psychopharmacology 62: 123-128, 1979.
49. MANN, J. J., AARONS, S. F , WILNER, P. J., KEILP, J. G., SWEENEY, J. A , PEARLSTEIN, T., FRANCES, A. J., KOCSIS, J. H. AND BROWN, R. P.: A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. Arch. Gen. Psychiatry 46: 45-50, 1989.
50. MANN, J. J. AND GERSHON, S : L-deprenyl, a selective monoamine oxidase type B inhibitor in endogenous depression. Life Sci. 26: 877-882, 1980.
51. MARTIN, L., BAKISH, D. AND JOFFE, R.: MAOI treatment of depression. In Clinical Advances in Monoamine Oxidase Inhibitor Therapies, ed. by S H. Kennedy, pp 147-180, American Psychiatry Press, Washington, D.C., 1994.
52. MENDIS, N., PARE, C. M. B., SANDLER, M , GLOVER, V. AND STERN, G M.: Is the failure of (-)-deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom form the cheese effect? Psychopharmacology 73: 87-90, 1981.
53. 3H]-naloxone binding site density after chronic administration of antidepressant agents. Eur. J. Pharmacol. 102: 179-181, 1984.
54. 3H]-5-HT binding sites and at the 5-HT autoreceptor by propranolol. Eur. J. Pharmacol. 101: 289-293, 1984.
55. MILLARD, S. A. AND GAL, E. M.: The contribution of 5-hydroxyindolepyruvic acid to cerebral 5-hydroxyindole metabolism. Intern. Neurosci. 1: 211-218, 1971.
56. MINAMIURA, N. AND YASUNOBU, K. T.: Bovine liver monoamine oxidase. A modified purification procedure and preliminary evidence for two subunits and one FAD. Arch. Biochem. Biophys. 189: 481-489, 1978.
57. MURPHY, D. L., AULAKH, C. S., GARRICK, N. A. AND SUNDERLAND, T.: Monoamine oxidase inhibitors as antidepressants: Implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In Psychopharmacology: The Third Generation of Progress, ed. by H. Y. Meltzer, pp. 545-552, Raven Press, New York, 1987.
58. 3 recognition sites in cortical membranes. Eur. J. Pharmacol. 148: 297-299, 1988.
59. PICKAR, D., COHEN, R. M., JIMERSON, D. C. AND MURPHY, D. L.: Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity. Psychopharmacology 74: 4-7, 1981.
60. PROVOST, J. C., FUNCK-BRENTANO, C., ROVEI, V., D' ESTANQUE, J., EGO, D. AND JAILLON, P.: Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase A inhibitor, and oral tyramine in healthy subjects. Clin. Pharmacol. Ther. 52: 384-393, 1992.
61. 3H]-dihydroalprenolol. Mol. Pharmacol. 36: 201-210, 1989.
62. ROBINSON, D. S., JOHNSON, G. A., NIES, A., CORCELLA, J., COOPER, T. B., ALBRIGHT, D. AND HOWARD, D.: Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. J. Clin. Psychopharmacol. 3: 282-287, 1983.
63. 3H-Ro 19-6327 in vitro: Localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci. 12: 1977-1999, 1992.
64. SCATTON, B.: Brain 3,4-dihydroxyphenylethyleneglycol levels are dependent on central noradrenergic neuron activity, Life Sci. 31: 495-504, 1982.
65. SCHEININ, M., KARHUVAARA, S., OJALA-KARLSSON, P., KALLIO, A. AND KOULU, M.: Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of α2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci. 49: 75-84, 1991.
66. SCHEININ, M., KOULU, M., KARHUVAARA, S. AND ZIMMER, R. H.: Evidence that the reversible MAO A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers. Life Sci. 47: 1491-1499, 1990.
67. SHIH, J. C.: Molecular basis of human MAO A and B. Neuropsychopharmacology 4: 1-7, 1991.
68. STROLIN-BENEDETTI, M., BOUCHER, T., CARLSSON, A. AND FOWLER, C. J.: Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem. Pharmacol. 32: 47-52, 1983.
69. STROLIN-BENEDETTI, M. AND DOSTERT, P.: Stereochemical aspects of MAO interactions: Reversible and selective inhibitors of monoamine oxidase. Trends Pharmacol Sci. 6: 246-251, 1985.
70. THORPE, L. W., WESTLUND, K. N., KOCHERSPERGER, L. M., ABELL, C. W. AND DENNEY, R. M.: Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. J. Histochem. Cytochem. 35: 23-32, 1987.
71. WALDMEIER, P. C.: Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). J. Neural Transm. 23: (Suppl.) 55-72, 1987.
72. WALDMEIER, P. C. AND BAUMANN, P. A.: Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 324: 20-26, 1983.
73. WALDMEIER, P. C., FELNER, A. E. AND LAUBER, J.: Reversible monoamine oxidase inhibitors: Relation between effects on enzymatic activity measured ex vivo and on amine metabolism. In Monoamine Oxidase and Disease, ed. by K. Tipton, P. Dostert and M. Strolin-Benedetti, pp. 107-116, Academic Press, London, 1984.
74. WALDMEIER, P. C., FELNER, A. E. AND TIPTON, K. F.: The monoamine oxidase inhibiting properties of CGP 11305 A. Eur. J. Pharmacol. 94: 73-83, 1983.
75. 3H]tolyl)-guanidine: A selective ligand that labels σ-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. U.S.A. 83: 8784-8788, 1986.
76. WESTLUND, K. N., DENNEY, R. M., KOCHERSPERGER, L. M., ROSE, R. M. AND ABELL, C. W.: Distinct monoamine oxidase A and B populations in primate brain. Science (Wash. DC) 230: 181-183, 1985.
77. WESTLUND, K. N., DENNEY, R. M., ROSE, R. M. AND ABELL, C. W.: Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25: 439-456, 1988.
78. WESTLUND, K. N., KRAKOWER, T. J., KWAN, S. W. AND ABELL, C. W.: Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res. 612: 221-230, 1993.
79. WHEATLEY, D.: Comparative trial of a new mono-amineoxidase inhibitor in depression. Br. J. Psychiatry 117: 573-574, 1970.
80. WHITE, H. L. AND SCATES, P. W.: Mechanism of monoamine oxidase-A. inhibition by BW1370U87. Drug Dev. Res. 25: 191-199, 1992.
81. WILLOUGHBY, J., GLOVER, V. AND SANDLER, M.: Histochemical localization of monoamine oxidase A and B in rat brain. J. Neural Transm. 74: 29-42, 1988.
82. WOLF, W. A., YOUDIM, M. B. H. AND KHUN, M.: Does brain 5-HIAA indicate serotonin release or monoamine oxidase activity?. Eur. J. Pharmacol. 109: 381-387, 1985.
83. YOKOYAMA, T., KARUBE, T. AND IWATA, N.: Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain. J. Pharm. Pharmacol. 41: 32-36, 1989.
84. YOUDIM, M. B. H. AND FINBERG, J. P. M.: Monoamine oxidase inhibitor antidepressants. In Psychopharmacology 2. Part 1. Preclinical Psychopharmacology, ed. by D. G. Grahame-Smith, pp. 35-70, Elsevier Science Publishers B. V., Amsterdam, 1985.
85. YOUDIM, M. B. H., FINBERG, J. P. M. AND TIPTON, K. F.: Monoamine oxidase. In Catecholamines. I. Handbook of Experimental Pharmacology, Vol. 90, ed. by U. Trendelenburg and N. Weiner, pp. 119-192, Springer-Verlag, Berlin, 1988.